Initial management of high risk early stage prostate cancer

Radiation

Eric M. Horwitz, Steven J. Feigenberg, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following high-risk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.

Original languageEnglish (US)
Title of host publicationTreatment Methods for Early and Advanced Prostate Cancer
PublisherCRC Press
Pages205-211
Number of pages7
ISBN (Electronic)9780203091432
ISBN (Print)0415458935, 9780415458931
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Risk Management
Prostatic Neoplasms
Radiation
Neoplasm Grading
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2008). Initial management of high risk early stage prostate cancer: Radiation. In Treatment Methods for Early and Advanced Prostate Cancer (pp. 205-211). CRC Press.

Initial management of high risk early stage prostate cancer : Radiation. / Horwitz, Eric M.; Feigenberg, Steven J.; Pollack, Alan.

Treatment Methods for Early and Advanced Prostate Cancer. CRC Press, 2008. p. 205-211.

Research output: Chapter in Book/Report/Conference proceedingChapter

Horwitz, EM, Feigenberg, SJ & Pollack, A 2008, Initial management of high risk early stage prostate cancer: Radiation. in Treatment Methods for Early and Advanced Prostate Cancer. CRC Press, pp. 205-211.
Horwitz EM, Feigenberg SJ, Pollack A. Initial management of high risk early stage prostate cancer: Radiation. In Treatment Methods for Early and Advanced Prostate Cancer. CRC Press. 2008. p. 205-211
Horwitz, Eric M. ; Feigenberg, Steven J. ; Pollack, Alan. / Initial management of high risk early stage prostate cancer : Radiation. Treatment Methods for Early and Advanced Prostate Cancer. CRC Press, 2008. pp. 205-211
@inbook{bc84640dcf9b454f9da6790b461c9fac,
title = "Initial management of high risk early stage prostate cancer: Radiation",
abstract = "Introduction Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following high-risk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.",
author = "Horwitz, {Eric M.} and Feigenberg, {Steven J.} and Alan Pollack",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
isbn = "0415458935",
pages = "205--211",
booktitle = "Treatment Methods for Early and Advanced Prostate Cancer",
publisher = "CRC Press",

}

TY - CHAP

T1 - Initial management of high risk early stage prostate cancer

T2 - Radiation

AU - Horwitz, Eric M.

AU - Feigenberg, Steven J.

AU - Pollack, Alan

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Introduction Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following high-risk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.

AB - Introduction Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following high-risk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85056529200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056529200&partnerID=8YFLogxK

M3 - Chapter

SN - 0415458935

SN - 9780415458931

SP - 205

EP - 211

BT - Treatment Methods for Early and Advanced Prostate Cancer

PB - CRC Press

ER -